🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Øystein Fluge,Norway, on plasma cell targeting in #MECFS: Daratumumab (anti-CD38) shows clinical &objective improvement in 60% of patients in a pilot trial. Findings support the role of long-lived plasma cells in disease mechanisms. The question is: Where is pharma? #MEAwareness

Judith Bellmann-Strobl (Charité) on B-cell depletion in postinfectious #MECFS: RCTs with anti-CD20/CD19 mAbs (Ocrelizumab, Inebilizumab) are underway. Pilot data after immunoadsorption show functional gains. Target: pathogenic autoantibodies. #MEAwarenessMonth

New Rituximab trial in #MECFS – launched in #Japan by Wakiro Sato (NCNP Tokyo): Neuroimmunology, autoantibodies & B-cell dysregulation in focus. A comprehensive design with functional & biomarker endpoints. Global research momentum is growing. #MEAwarenessMonth

Repeated immunoadsorption in #MECFS by Elisa Stein, Charité: Significant reduction of immunoglobulins and autoantibodies – but clinical effect often not sustained. Trial data highlight: responders exist – but why only some? The key may lie in B-cell targeting. #MEawarenessmonth

Immunoadsorption in severely ill ME/CFS patients, Georg Schlieper, Hannover: Case series show improvement in many, but not all. Controlled trials are urgently needed to understand who benefits and why. #MECFS #Immunoadsorption #MEAwareness #MillionsMissing

Low-dose Naltrexone (LDN) & Mestinon in ME/CFS: David Systrom, USA, presents early data suggesting potential benefit in improving cellular energy metabolism & neurovascular regulation. A promising approach in a challenging clinical landscape. #MECFS #LDN #Mestinon #ClinicalTrials

.Putrino Lab (Mount Sinai): Targeting muscle & mitochondrial dysfunction in ME/CFS. Low-dose rapamycin may help by reversing immunosenescence, enhancing T-cell function & stabilizing cytokine release. RCT now underway. #MECFS #Rapamycin #Mitochondria #MEAwarenessMonth

Follow-up from Day 2 of the #MECFS Conference: Preliminary results from a controlled HBOT trial in ME/CFS (Laura Kim, Charité). 40 sessions led to improvements in fatigue, pain, cognitive function, and physical capacity. Well tolerated. #HBOT #MillionsMissing #MEAwarenessMonth

Follow-up from Day 2 of the ME/CFS Conference: Nina Babel, Charité, presented mechanisms and clinical data on intravenous immunoglobulin (IVIG) in #MECFS and PCS. Immunomodulatory, anti- inflammatory effects –early RCT showed significant improvement. #MECFS #IVIG #MillionsMissing

So exciting to see multiple studies of immunomodulation in ME/CFS being reported at the international ME/CFS conference. Sadly catching up now but recordings of talks promised to follow. UK infrastructure & change approach urgently needed #ThereForME events.mecfs-research.org/en/events/conf…

Are we doing this again? This opinion piece calls for HOPE as a treatment of ME/CFS. Or does it? In 2021, NICE reviewed interventions. We already have evidence. ➡️Graded exercise and CBT don’t cure ME/CFS& GET can be harmful. ➡️The lightning process is not recommended.

Proud to sign this response amongst fantastic company. Can demonstrate pathology @ bedside. With targeted tests. Still time for 2020's to be decade for real progress towards targeted treatments, widespread acceptance/education & better supportive personalised care. We must.